Identification of Prognostic factor and Therapeutic target of Salivary Duct Carcinoma by Multi institutional study

• Project/Area Number: 20K09763
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 56050:Otorhinolaryngology-related
• Research Institution: Tokai University
• Principal Investigator: 大上 研二 東海大学, 医学部, 教授 (90223734)
• Project Period (FY): 2020-04-01 – 2024-03-31
• Project Status: Completed (Fiscal Year 2023)
• Budget Amount: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000); Fiscal Year 2023: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000); Fiscal Year 2022: ¥390,000 (Direct Cost: ¥300,000、Indirect Cost: ¥90,000); Fiscal Year 2021: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2020: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
• Keywords: Salivary Duct Carcinoma / 予後因子 / リンパ節転移 / 節外浸潤 / 遠隔転移 / 唾液腺導管癌 / 頭頸部癌 / 分子標的薬

Outline of Research at the Start

非常に予後不良な高悪性度唾液腺癌である唾液腺導管癌（Salivary Duct Carcinoma: SDC ）は、これまで単施設での少数例のSDCにより予後解析や適切な治療選択が議論されているが、有用な予後予測因子や新規治療は開発されていない。世界的にもまれに見る多数症例から得られた多施設共同研究で臨床データや病理組織学的検索結果、遺伝子解析データを解析する。そして治療困難なSDCの臨床病理学的予後因子の解析と有効な新規治療開発をおこなう。

Outline of Annual Research Achievements

唾液腺導管癌（Salivary Duct Carcinoma: SDC ）の予後予測因子や新規治療のための基礎的な研究をおこなった。多施設症例の手術病理検体を集積した。HE染色と免疫組織学的手法で脈管侵襲と転移リンパ節の節外浸潤について解析を行った。臨床病理的因子および生存率の関連を明らかにして、病理学的および臨床的予後因子について解析した。また分子生物学的な予後因子を多数のSDCの所見の集積と臨床病理学的因子の関連を解析し，SDCの病態の解明と治療に関する多くの知見が得られた。
単施設での症例集積には限界があるが，多施設共同研究で多くの症例を集積することで希少がんとしては他に例を見ない多症例での検討することで，より意義深い予後因子解析や治療標的分子の同定が可能となった．
Hirai H, Okami K, et al. Prognostic value and clinicopathological roles of the tumor immune microenvironment in salivary duct carcinoma. Virchows Arch. 2023 Sep;483(3):367-379.
Kohsaka S, Tada Y, Ando M, Nakaguro M, Shirai Y, Ueno T, Kojima S, Hirai H, Saigusa N, Okami K,et al. Identification of novel prognostic and predictive biomarkers in salivary duct carcinoma via comprehensive molecular profiling.
NPJ Precis Oncol. 2022 Nov 4;6(1):82.

Research Products

• [Journal Article] Prognostic value and clinicopathological roles of the tumor immune microenvironment in salivary duct carcinoma (2023)
  • Author(s): Hirai Hideaki、Nakaguro Masato、Tada Yuichiro、Saigusa Natsuki、Kawakita Daisuke、Honma Yoshitaka、Kano Satoshi、Tsukahara Kiyoaki、Ozawa Hiroyuki、Okami Kenji、Yamazaki Keisuke、Fushimi Chihiro、Kondo Takahito、Imanishi Yorihisa、Sakai Akihiro、Togashi Takafumi、Hanazawa Toyoyuki、Matsuki Takashi、Nagao Toshitaka
  • Journal Title: Virchows Archiv Volume: 483 Issue: 3 Pages: 367-379
  • DOI: 10.1007/s00428-023-03598-3
  • Peer Reviewed / Open Access
• [Journal Article] Identification of novel prognostic and predictive biomarkers in salivary duct carcinoma via comprehensive molecular profiling (2022)
  • Author(s): Kohsaka S, Tada Y, Okami K, et al.
  • Journal Title: NPJ Precis Oncol. Volume: 6 Issue: 1 Pages: 82-82
  • DOI: 10.1038/s41698-022-00324-1
  • Peer Reviewed / Open Access
• [Journal Article] Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma (2022)
  • Author(s): Kawakita Daisuke、Nagao Toshitaka、Takahashi Hideaki、Kano Satoshi、Honma Yoshitaka、Hirai Hideaki、Saigusa Natsuki、Akazawa Kohei、Tani Kaori、Ojiri Hiroya、Tsukahara Kiyoaki、Ozawa Hiroyuki、Okami Kenji、Kondo Takahito、Togashi Takafumi、Fushimi Chihiro、Shimura Tomotaka、Matsuki Takashi、Tada Yuichiro
  • Journal Title: Therapeutic Advances in Medical Oncology Volume: 14 Pages: 175883592211195-175883592211195
  • DOI: 10.1177/17588359221119538
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy (2022)
  • Author(s): Saigusa N, Hirai H, Kohsaka S, et al.
  • Journal Title: Front Oncol Volume: 11 Pages: 779882-779882
  • DOI: 10.3389/fonc.2021.779882
  • Peer Reviewed / Open Access
• [Journal Article] The significance of tyrosine kinase receptor B and brain-derived neurotrophic factor expression in salivary duct carcinoma (2021)
  • Author(s): Yusuke Kondo, K Hirabayashi, Joaquim Carreras , Keiichi Tsukinoki, Yoshihide Ota, Kenji Okami, Naoya Nakamura
  • Journal Title: Ann Diagn Pathol . Volume: - Pages: 151673-151673
  • DOI: 10.1016/j.anndiagpath.2020.151673
  • Peer Reviewed / Int'l Joint Research
• [Journal Article] Prognostic Implication of Histopathologic Indicators in Salivary Duct Carcinoma (2020)
  • Author(s): Nakaguro Masato、Sato Yukiko、Tada Yuichiro、Kawakita Daisuke、Nagao Toshitaka et al.
  • Journal Title: The American Journal of Surgical Pathology Volume: 44 Issue: 4 Pages: 526-535
  • DOI: 10.1097/pas.0000000000001413
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] The clinicopathological significance of the adipophilin and fatty acid synthase expression in salivary duct carcinoma. (2020)
  • Author(s): Hirai H、Tada Y、Nakaguro M、Kawakita D、Sato Y、Shimura T、Tsukahara K、Kano S、Ozawa H、Okami K、Sato Y、Fushimi C、Shimizu A、Okamoto I、Takase S、Okada T、Sato H、Imanishi Y、Otsuka K、Watanabe Y、Sakai A、Ebisumoto K、Togashi T、Ueki Y、Ota H、Saigusa N、Takahashi H、Ando M、Urano M、Hanazawa T、Nagao T
  • Journal Title: Virchows Arch Volume: X Issue: 2 Pages: 291-299
  • DOI: 10.1007/s00428-020-02777-w
  • Peer Reviewed / Open Access / Int'l Joint Research